Veen-3G Injection BAG 20×500mL(ヴィーン3G輸液，醋酸钠/葡萄糖注射剂)
药店国别：
产地国家：
日本
处 方 药：
是
所属类别：
500毫升/袋 20袋/盒
包装规格：
500毫升/袋 20袋/盒
计价单位：
盒
生产厂家中文参考译名:
扶桑薬品
生产厂家英文名:
Fuso Pharmaceutical Industries,Ltd.
该药品相关信息网址1:
该药品相关信息网址2:
该药品相关信息网址3:
原产地英文商品名:
Veen-3G（ヴィーン3G輸液）500ml/bag 20bag/box
原产地英文药品名:
sodium acetate/glucose
中文参考商品译名:
Veen-3G（ヴィーン3G輸液）500毫升/袋 20袋/盒
中文参考药品译名:
醋酸钠/葡萄糖
曾用名:
简介：
部份中文醋酸钠/葡萄糖輸液处方资料（仅供参考）
英文名：sodium acetate/glucose
商品名：Veen-3G Injection
中文名：醋酸钠/葡萄糖輸液
生产商：扶桑薬品
药品简介 Veen 3G是一种含有5%葡萄糖的醋酸盐电解质溶液，用于被判断为完全或部分不能通过口服或肠内途径摄入维持液的术后儿科患者。 ヴィーン3G輸液（200mLバッグ）/ヴィーン3G輸液（500mLバッグ）
药效分类名称
葡萄糖加醋酸维持液
批准日期：2017年8月
商標名
Veen-3G Injection
3G输液（500mL袋）
組成
有効成分
日药典葡萄糖 25.0g
日药典氯化钠 730.6mg
日药典氯化钾 261.0mg
日药典醋酸钠水合物 1360.8mg
磷酸二氢钾 680.5mg
氯化镁 254.2mg
添加剤 pH调节剂适量
热量 100卡
电解质浓度（毫克当量/升：理论值）
Na＋45
K＋17
Mg2＋5
Cl－37
H2PO4－10
CH3COO－20
剤形：水性注射剤
使用上的注意事项
因为是液体泄漏的原因，所以要避免强烈的冲击和与尖锐的东西接触等。
以下情况下请勿使用。
在外袋内或容器表面发现水滴或结晶时
药液从容器泄漏时
性状及其他药液出现异状时
橡胶栓部的密封脱落时
药效药理
作用机制
本制剂显示了水分、电解质及能量的补给效果。
对体重的影响
将本制剂对饥饿禁食时家兔的效果与麦芽糖加醋酸维持液、葡萄糖加醋酸维持液及醋酸维持液进行比较，结果显示体重变化无差异。
适应症
不能经口摄取或不充分时的水分、电解质的补给、维持、能量的补给
用法与用量
成人每次滴注500～1000mL，儿童每次滴注200～500mL。关于给药速度，成人、儿童均以葡萄糖计，为每小时0.5g/kg体重以下。另外，根据年龄、症状、体重等适当增减。
包装
200毫升 20袋软袋
500毫升 20袋软袋
制造商和分销商
扶桑薬品工業株式会社 注：以上中文处方资料不够完整，使用者以原处方资料附件。
完整说明书附件： https://www.info.pmda.go.jp/go/pack/3319562A1065_2_04/
---------------------------------------------------
Clinical experience with NIK-716(Veen® 3G Inj[Glucose,Sodium Chloride,Potassium Chloride,Magnesium Chloride,Potassium Phosphate Monobasic,Monosodium Acetate Trihydrate]) in pediatrics
The maintenance fluid Veen® 3G Inj.acetated electrolyte solution containing 5% glucose, was administered to postoperative pediatric patients who were judged to be completely or partially unable to take a maintenance fluid by the oral or enteral route and require intravenous replacement of water, electrolytes and energy. Veen® 3G Inj. was administered by intravenous infusion for up to 24 hours from postoperative day 1(POD1).
Blood chemistry examination and urinalysis were performed before and after administration to assess the following three variables:(1)the replacement and maintenance of water (assessment of hydration and urine output); (2) the maintenance of serum electrolytes(Na and K); and(3)the utilization of glucose (blood glucose and urinary glucose). Having these variables within normal range was regarded as the indicator of efficacy of a maintenance fluid.
Veen® 3G Inj. proved effective in maintaining these variables within normal in all (100%) of the 25 pediatric patients who were eva luable for efficacy. As for its safety, Veen® 3G Inj.
produced no adverse events or abnormal laboratory values attributable to its infusion in any of the 29 children who received it and was thus judged to have posed no safety problem. The results obtained in this study where Veen® 3G Inj.was administered to postoperative pediatric patients suggest that Veen® 3G Inj.is a clinically useful and highly safe maintenance fluid.])in pediatrics
The maintenance fluid Veen® 3G Inj.acetated electrolyte solution containing 5% glucose, was administered to postoperative pediatric patients who were judged to be completely or partially unable to take a maintenance fluid by the oral or enteral route and require intravenous replacement of water, electrolytes and energy. Veen® 3G Inj. was administered by intravenous infusion for up to 24 hours from postoperative day 1(POD1).
Blood chemistry examination and urinalysis were performed before and after administration to assess the following three variables:(1)the replacement and maintenance of water (assessment of hydration and urine output); (2) the maintenance of serum electrolytes(Na and K); and(3)the utilization of glucose (blood glucose and urinary glucose). Having these variables within normal range was regarded as the indicator of efficacy of a maintenance fluid.
Veen® 3G Inj. proved effective in maintaining these variables within normal in all (100%) of the 25 pediatric patients who were eva luable for efficacy. As for its safety, Veen® 3G Inj.
produced no adverse events or abnormal laboratory values attributable to its infusion in any of the 29 children who received it and was thus judged to have posed no safety problem. The results obtained in this study where Veen® 3G Inj.was administered to postoperative pediatric patients suggest that Veen® 3G Inj.is a clinically useful and highly safe maintenance fluid.
